Final answer:
McGoy Ltd should account the $510,000 research expenditure as an expense, capitalize the $780,000 prototype development and the $25,000 patent registration as intangible assets, and expense the $2,200,000 marketing costs. An offer to buy the patent cannot change its initial cost valuation in the financial statements.
Step-by-step explanation:
McGoy Ltd's expenditure on research and development should be accounted for in accordance with the International Accounting Standards (IAS) particularly IAS 38 'Intangible Assets'. Firstly, the $510,000 on research is considered an expense and should be recognized in the income statement when incurred because it does not meet the capitalization criteria as an intangible asset. Then, the $780,000 on development of the prototype can be capitalized since it meets the criteria of being able to generate probable future economic benefits. This amount should be added to the company's intangible assets on the balance sheet. The legal cost of $25,000 for patent registration should also be capitalized as a part of the intangible asset given that the patent is controllable, identifiable, and expected to produce future economic benefits. The subsequent marketing costs of $2,200,000 are to be expensed in the income statement, as marketing costs are typically recognized as an expense.
Regarding the offer from the competitor to buy the patent for $150 million, this cannot be recognized in the financial statements, because valuation of an intangible asset is based on the cost model (historical cost or amortized cost), not on market offers or fair value. Even if the managing director wants to reflect the present value, accounting standards require intangible assets to be recorded at cost and not at their potential market value. However, such a valuation might be disclosed in the notes to the financial statements, providing investors with information about the offer.